Egetis Therapeutics AB (publ) (STO:EGTX)
Sweden · Delayed Price · Currency is SEK 6.07
+0.46 (8.20%)
May 4, 2026, 5:29 PM CET
Egetis Therapeutics AB Company Description
Egetis Therapeutics AB (publ), a pharmaceutical company, engages in the development and commercialization of orphan drugs in Sweden and internationally.
It develops Aladote, which is in Phase IIb/III clinical trial for the treatment of paracetamol/acetaminophen overdosing and for the prevention of acute liver failure in paracetamol poisoning; and Emcitate, which is in Phase IIb clinical trial for the treatment of monocarboxylate transporter 8 deficiency.
The company was formerly known as PledPharma AB (publ) and changed its name to Egetis Therapeutics AB (publ) in December 2020.
Egetis Therapeutics AB (publ) was incorporated in 2006 and is headquartered in Stockholm, Sweden.
Egetis Therapeutics AB (publ)
| Country | Sweden |
| Founded | 2006 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 42 |
| CEO | Nicklas Westerholm |
Contact Details
Address: Klara Norra Kyrkogata 26 Stockholm, 111 22 Sweden | |
| Phone | 46 86 79 72 10 |
| Website | egetis.com |
Stock Details
| Ticker Symbol | EGTX |
| Exchange | Nasdaq Stockholm |
| Fiscal Year | January - December |
| Reporting Currency | SEK |
| ISIN Number | SE0003815604 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Nicklas Westerholm | Chief Executive Officer |
| Torsten Almén | Founder |
| Dr. Ingemar Lundström Ph.D. | Founder |
| Dr. Louis Joseph Ignarro Ph.D. | Founder |
| Associate Prof. Heidi Brurok | Founder |
| Dr. Rob Towart | Founder |
| Dr. Yilmaz Mahshid Ph.D. | Chief Financial Officer |
| Dr. Katayoun Welin-Berger Ph.D. | Vice President of Operations |
| Dr. Karl Hard Ph.D. | Head of Investor Relations and Business Development |
| Laetitia Szaller L.L.M. | General Counsel and Head of Compliance and ESG |